FDA Approves Atebrioz (Zilurgisertib) For Fibrodysplasia Ossificans Progressiva In Adults & Pediatric Patients 12+ Years; Atebrioz Recommended Dosage 100mg Once Daily

The FDA has approved Atebrioz (Zilurgisertib) for the treatment of Fibrodysplasia Ossificans Progressiva in adults and pediatric patients aged 12 years and older. The recommended dosage for Atebrioz is 100mg once daily. This marks a significant advancement in treatment options for this rare condition, potentially impacting the stock performance of Incyte Corporation (ticker: INCY).